Fresh Win For AstraZeneca/Merck & Co Pact With Koselugo Approval

First Medicine In EU For Rare Condition NF1

Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.

eu flags
Europe waves through Koselugo • Source: Alamy

Another milestone in the successful oncology collaboration between AstraZeneca PLC and Merck & Co., Inc. has been reached with approval in Europe granted to Koselugo, the firm's therapy for neurofibromatosis type 1 (NF1), a rare debilitating genetic condition.

Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Commission...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip